

SYNTHESIS, CHARACTERIZATION AND ANTIMICROBIAL SCREENING OF NEW NICKEL (II) METAL COMPLEXES INCORPORATING SCHIFF BASES

Shivshankar G. Gaikwad¹, Shivdeep S. Deshmukh¹, Rajesh K. Manjul², Dhananjay N. Gaikwad³, Vishal N. Kadam¹, Mahadev V Gaikwad¹, Tukaram B. Mhamane¹, Sayabu P. Dapegave¹, Maruti R. Pethkar¹, Jaiprakash N. Sangshetti⁴, Aajali S. Rajbhoj⁵ and Suresh T. Gaikwad^{5*}

¹Baburao Patil College of Arts and Science, Angar, Solapur- 413214

²SMBST College, Sangamner-422605

³Yashavantrao Chavan Institute of Science, Satara, 415001

⁴Y. B. Chavan College of Pharmacy Rauza Baugh Aurangabad (MS) – 431001

⁵Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Chha. Sambhajinagar (MS) – 431004

Corresponding author: Suresh T. Gaikwad

Keywords: Schiff Base Ni (II) Complexes, Antifungal & Antibacterial Activity.


Abstract

In this, research four Schiff bases ligand (L₁-L₄) and its Ni (II) Complexes (CL₁-CL₄) synthesized and characterized. These complexes were synthesized using the ligands listed above and NiCl₂.6H₂O in a 1:1 stoichiometric ratio. Synthesized ligands were characterized by using ¹H NMR, ¹³C NMR, UV-Visible, FT-IR, and HRMS techniques. The Ni (II) complexes were characterized by using UV-Visible, FT-IR, and TGA techniques. These complexes and ligands exhibit significant antibacterial activity over four distinct human pathogenic bacterial strains such as gram-negative *Escherichia coli*, *Pseudomonas aeruginosa*, and gram-positive *Staphylococcus aureus* and *Bacillus subtilis* whereas antifungal activity against *Candida albicans* and *Aspergillus niger* fungal strains.

Introduction

Currently, there has been an increase of drug-resistant in bacteria. This is directly linked to higher mortality rates from infectious illnesses. Therefore need of search of new drugs [1, 2]. Coordination complexes increasingly replace traditional organic drugs. Zinc, calcium, iron, and cobalt metals exhibit significant biological effects when combined with Schiff base ligand. Recently, Inorganic materials like metal and metal oxides have gained increased attention because they are typically safe for both humans and animals. Oxides of transition metals are made up of oxygen atoms attached to transition metals [3].

Schiff bases were used in a variety of fields like biology, medicine, and catalysis [4, 5]. Schiff base complexes contributed to significant developments in coordination and stereochemistry [6, 7]. From last 12 years, many advances and new techniques have been discovered for synthesis of Schiff base including solvent-free, clay, solid-state synthesis, K-10/microwave, BF₄/molecular sieves water

Figure1: Structure of Ligands **L₁-L₄****Spectral data of Ligands****2,2'-((1E,1'E)-(((1,3-phenylenebis(oxy)))bis(4,1-phenylene))bis(azanylylidene))bis(methanylylidene))diphenol (**L₁**)**

Yield: 81 %; mp: 106-108°C; FT-IR (KBr, v/cm^{-1}): 3401 (OH), 3048 (Ar-C-H), 1618 (C=N), 1566 (C=C), 1584, (C-O) 1266, 1209, 1183, 1127; ^1H NMR (400 MHz, CDCl_3) \square ppm: 13.25 (2H, s, Ar-OH) 8.55 (2H, s, Azomethine) 7.44 - 7.51 (d, 5 H) 7.33 - 7.35 (s, 1 H) 7.29 - 7.32 (m, 3 H) 7.28 (s, 1 H) 7.11 - 7.12 (t, 3 H) 7.08 - 7.10 (t, 2 H) 6.94 (s, 1 H) 6.92 (s, 1 H) 6.81 (d, $J=2.25$ Hz, 1 H) 6.79 (d, $J=2.38$ Hz, 1 H) 6.74 - 6.75 (t, 1 H); ^{13}C NMR (101 MHz, CDCl_3) $\square\square$ ppm: 159.94, 159.73, 158.09, 155.78, 143.14, 135.29, 133.81, 130.35, 122.32, 120.27, 119.59, 118.92, 113.34, 110.21, 109.26, 76.89, 76.68, 76.36; Mass (m/z): 501.18 [$M+1$].

2,2'-((1E,1'E)-(((1,3-phenylenebis(oxy)))bis(4,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(4-chlorophenol) (L₂**)**

Yield: 79 %; mp: 174-176 °C; FT-IR (KBr, v/cm^{-1}): 3418 (OH), 3071 (Ar-C-H), 1619 (C=N), 1506 (C=C), 1378, 1358, 1260, 1240 (C-O); ^1H NMR (400 MHz, CDCl_3) \square ppm 13.20 (2H, s, Ar-OH) 8.54 (2H, s, Azomethine) 7.35 (d, $J=2.50$ Hz, 2 H) 7.31 - 7.33 (m, 2 H) 7.29 (m, 3 H) 7.25 (s, 1 H) 7.09 - 7.10 (t, 3 H) 7.07 - 7.08 (t, 2 H) 6.97 (s, 1 H) 6.95 (s, 1 H) 6.79 (d, $J=2.25$ Hz, 1 H) 6.77 (d, $J=2.38$ Hz, 1 H) 6.72 - 6.73 (t, 1 H) ^{13}C NMR (101 MHz, CDCl_3) \square ppm 160.42, 159.61, 158.45, 156.11, 143.54, 132.85, 131.15, 130.68, 123.72, 122.65, 119.95, 118.83, 113.68, 109.58, 77.34, 77.22, 77.02, 76.70. Mass (m/z): 569.10 [$M+1$].

2,2'-((1E,1'E)-(((1,3-phenylenebis(oxy)))bis(4,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(4-bromophenol) (L₃**)**

Yield: 80 %; mp: 158-160°C FT-IR (KBr, v/cm^{-1}): 3423 (OH), 2978 (Ar-C-H), 1606 (C=N), 1504 (C=C), 1383, 1272, 1240, 1228 (C-O); ^1H NMR (400 MHz, CDCl_3) $\square\square$ ppm 13.24 (2H, s, Ar-OH) 8.53 (2H, s, Azomethine) 7.49 - 7.50 (d, $J=2.50$ Hz, 2 H) 7.44 - 7.45 (d, $J=2.50$ Hz, 1 H) 7.42 (d, $J=2.38$ Hz, 1 H) 7.28 - 7.33 (m, 4 H) 7.25 (s, 1 H) 7.09 - 7.11 (t, 2 H) 7.07 - 7.08 (t, 2 H) 6.93 (s, 1 H) 6.90 (s, 1 H) 6.79 - 6.80 (d, $J=2.25$ Hz, 1 H) 6.77 (d, $J=2.38$ Hz, 1 H) 6.72 - 6.74 (t, 1 H); ^{13}C NMR (101 MHz,

CDCl₃) □ ppm 161.88, 161.02, 158.58, 155.64, 144.13, 133.06, 132.18, 130.57, 122.54, 119.95, 119.18, 119.08, 117.22, 113.38, 109.32, 77.32, 76.68. 569. Mass (m/z): 658.99[M+1].

2,2'-((1E,1'E)-(((1,3-phenylenebis(oxy))bis(4,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(4-methylphenol) (L₄)

Yield: 78 % mp:138-140°C FT-IR (KBr, v/cm⁻¹): 3425(OH), 2925 (Ar-C-H), 1614 (C=N), 1497 (C=C), 1384,1288,1263,1225 (C-O); ¹H NMR (400 MHz, CDCl₃) □ ppm 12.99 (2H, s, Ar-OH) 8.57 (2H, s, Azomethine) 7.31 (s, 1 H) 7.29 (s, 1 H) 7.29 (s, 1 H) 7.28 (s, 1 H) 7.26 (s, 1 H) 7.20 (d, 1 H) 7.18 (s, 3 H) 7.10 - 7.11 (t, 2 H) 7.07 - 7.08 (t, 2 H) 6.94 (d, 1 H) 6.91 - 6.93 (d, 1 H) 6.78 - 6.79 (d, *J*=2.38 Hz, 1 H) 6.76 - 6.77 (d, 1 H) 6.72 - 6.75 (t, 1 H) 2.32 (s, 6 H) ¹³C NMR (101 MHz, CDCl₃) □ ppm 161.70, 155.35, 144.09, 133.77, 131.95, 130.35, 122.30, 119.74, 116.77, 115.79, 113.14, 109.09, 20.14, 9.63. Mass (m/z): 529.21[M+1].

Synthesis of Ni (II) Complexes (CL₁-CL₄)

An ethanoic solution of 0.1 M (5.00 g in 25 mL of ethanol) of the Schiff base ligand L₁ was added to a Ni (II) chloride solution of 0.102 M (2.59 g in 10 mL of ethanol). The above reaction mixture was refluxed under continuous stirring for about 6 h. The progress of reaction was checked by TLC and spots were visualized under UV light. The precipitate obtained was then filtered, washed thoroughly with ethanol, and dried in desiccator over anhydrous CaCl₂. Ni (II) complexes with other Schiff bases L₂ (5.69 g), L₃ (6.55 g) and L₄ (5.28 g) were synthesized using the above procedure. The synthesized complexes are characterized using physio-chemical techniques. The tentative structures of the prepared complexes are depicted in Figure-2




Figure-2: Structure of Complexes (CL₁ to CL₄).

Antibacterial activity

The antibacterial activity of the compounds was performed by enumerating the viable number of cells upon in the nutrient broth containing various concentrations of compounds. The viable number is represented by colony count method. The test organisms used on which the antibacterial activity was performed were *Escherichia coli* (NCIM2256), *Pseudomonas aeruginosa* (NCIM-2036), *Bacillus subtilis* (NCIM2063) and *Staphylococcus aureus* (NCIM-2901). In this method, the cells of test organisms were grown in nutrient broth till mid log phase and used as an inoculum for performing antimicrobial test. An approximately, 1×10^5 cells/mL test organisms were each inoculated with 0 to 500 µg/mL concentration of different compounds, separately, and each incubated for 16 to 18 h at 37 °C. During this incubation, cells tend to grow and multiply in number. However, if the compounds interfere with growth of cells, the numbers of cells decrease. After 16 to 18 h, viable numbers of cells were recorded by spreading an aliquot from the broth inoculated with test organisms and compounds as colony forming units per milliliter (CFU/mL). Minimum inhibitory concentration (MIC) was determined Ampicillin was used as standards for the comparison of antibacterial activity.

Antifungal Activity

Antifungal activity was determined by dilution method as per CLSI (formerly, NCCLS)

guidelines. The synthesized compounds and standard miconazole were dissolved in DMSO solvent. The medium yeast nitrogen base was dissolved in phosphate buffer pH 7 and it was autoclaved at 110 °C for 10 min. With each set a growth control without the antifungal agent and solvent control DMSO were included. The fungal strains were freshly subcultured onto Sabouraud dextrose agar (SDA) and incubated at 25 °C for 72 h. The fungal cells were suspended in sterile distilled water and diluted to get 10^3 cells/mL. Ten microliters of standardized suspension was inoculated onto the control plates and the media incorporated with the antifungal agents. The inoculated plates were incubated at 25 °C for 48 h. The readings were taken at the end of 48 and 72 h. The MIC was the lowest concentration of drug preventing growth of macroscopically visible colonies on drug containing plates when there was visible growth on the drug free control plates.

RESULTS AND DISCUSSION

The synthesized Schiff bases were found to be similar to the predicted results. Chemical and physical properties for every synthesized Schiff bases (L_1 to L_4) and Complexes (CL_1 to CL_4) are shown in Table 1. The molecular formula and compound values predicted theoretically and those observed from experimentation match very well.

Electronic Spectral Studies

Two bands might be seen in the UV–visible spectrum of the Schiff bases (L_1 – L_4). (Fig. 3). Due to the azomethine group $n \rightarrow \pi^*$ transition observed and a bright band in the 350–360 nm region [24, 25]. Three bands of absorption were seen in every complex. The first two were in 324 and 343 nm corresponding to the aromatic ring's $\pi \rightarrow \pi^*$ transition, while the third one was between 413 and 424 nm, corresponding to the azomethine group's ($C=N$) $n \rightarrow \pi^*$ transition [26].




Fig. 3- UV of Schiff base Ligand and Complexes

Table -1 Analytical and Physical data of Compound studied

Sr. No.	Compound	Molecular Formula	Color	Melting Point
1.	L ₁	C ₃₂ H ₂₄ N ₂ O ₄	Light Yellow	106 -108
2.	L ₂	C ₃₂ H ₂₂ Cl ₂ N ₂ O ₄	Pale Yellow	174 –176
3.	L ₃	C ₃₂ H ₂₂ Br ₂ N ₂ O ₄	Orange	158 - 160
4.	L ₄	C ₃₄ H ₂₈ N ₂ O ₄	Orange (Shining with Crystal)	138 - 142
5.	CL ₁	C ₃₂ H ₂₆ N ₂ O ₆ Ni	Brown	> 250
6.	CL ₂	C ₃₂ H ₂₄ Cl ₂ N ₂ O ₆ Ni	Brown	> 250
7.	CL ₃	C ₃₂ H ₂₄ Br ₂ N ₂ O ₆ Ni	Brown	> 250
8.	CL ₄	C ₃₄ H ₃₀ N ₂ O ₆ Ni	Brown	> 250

FT-IR spectral studies

The FT-IR spectra showed the significant stretching frequencies associated with groups such as enolic –OH, azomethine C=N-, aromatic C= C, -CO-, etc. In the range of 3401–3426 cm⁻¹ phenolic–OH stretching vibrations are seen likewise, azomethine stretching, shown in the range of 1594–1624 cm⁻¹. It is a significant functional group [27]. Interestingly, all of the Ni (II) complexes showed a decrease in this frequency at about 1618–1624 cm⁻¹, suggesting that the imine nitrogen atom was involved in coordination with the metal ion [28]. The substituted salicylaldehyde's -OH stretching and bending vibrational frequencies were observed in the 3401–3425 cm⁻¹ range. The coordination occurs through the enolic–OH group, as seen by the absence of these peaks in the spectra of all the nickel complexes. Additionally, the Ni (II) complexes show broad band at around 3412–3432 cm⁻¹ indicates the presence of coordinate water molecules to the core metal ion [29, 30]. The existence of ν (M-N) bands in the 556–573 cm⁻¹ frequency range provides additional confirmation that the azomethine nitrogen is coordinated [31, 32]. Significant characteristic band in the FT - IR spectra of prepared Schiff bases ligand and its complexes were shown in **Table – 2**

Table – 2 FT- IR spectra of ligand L₁ & Complex CL₁

Sr. No	Compound	ν (OH/ H ₂ O/CH)	ν (C=N)	ν (M-O)	ν (M-N)
1.	L ₁	3401	1618	-	-
2.	L ₂	3418	1610	-	-
3.	L ₃	3423	1606	-	-
4.	L ₄	3425	1594	-	-

5.	CL ₁	3432	1620	437	496
6.	CL ₂	3384	1619	457	512
7.	CL ₃	3426	1618	412	503
8.	CL ₄	3412	1624	443	532

¹H NMR spectral studies

For all synthesized Schiff base ligand, the ¹H NMR spectra were recorded in CDCl₃ solvent and expressed in parts per million. The synthesized Schiff base ligand show ¹H NMR spectra signals at 6.72–7.50 ppm that are produced by aromatic protons. A singlet that was detected downfield at 12.99–13.25 ppm in the ¹H NMR spectra of the Schiff base ligands and that integrated for two proton is attributed to –OH [33]. Similarly, there is a singlet signal at 8.53–8.57 ppm that is the result of the azomethine proton, which is attached to the carbon nearby the nitrogen atom [34].

Mass spectral analysis

The mass spectra of all the Schiff base ligands exhibit parent ion peaks, due to their respective molecular ion (M+1), corresponding to the molecular weight and confirming their molecular composition. The proposed molecular formula of these compounds was confirmed by comparing their molecular formula weights with the *m/z* values

Mass spectra of the Schiff base ligand L₁ are depicted in Fig. 4




Fig. 4 - Mass spectra of the Schiff base ligand L₁

Antimicrobial and antifungal activity

The in vitro antimicrobial activity i.e. Antibacterial and antifungal activities of each produced four ligands (L₁, L₂, L₃ and L₄) and four Complexes (CL₁, CL₂, CL₃ and CL₄) have been investigated and the results are collectively shown in Table 3 below. The dilution method has been employed in this

instance for calculating the Minimum Inhibitory Concentration (MIC) [35 - 37]. To study the in vitro antibacterial activity of ligands and Complexes we have screened all the synthesized ligands against four different human pathogenic bacterial strains namely gram negative *Escherichia coli*, *Pseudomonas aeruginosa* and gram positive *Staphylococcus aureus*, *Bacillus subtilis*. To study the in vitro antifungal activity of ligands and complexes, we have screened all the synthesized ligands against two different human pathogenic fungal strains namely *Candida albicans* and *aspergillus Niger*. Here, we have used *Ampicillin* as standard antibacterial activity and *Miconazole* as standard for an antifungal activity to compare the biological activity results of screened ligands and complexes. The bioactivity results showed that most of the synthesized complexes possess better antibacterial activity against the tested bacterial strains as compared to Ampicillin. The Complex of CL₃ act as the most active antibacterial agent and show better antibacterial activity with MIC 109 ± 0.21 , 278 ± 0.47 , 106 ± 0.34 and 111 ± 0.66 , respectively against all four different tested human pathogenic bacterial strains used in this study. The other synthesized Complexes were also shows a better antibacterial activity with MIC value CL₁ 115 ± 0.94 , 121 ± 0.74 , 209 ± 0.37 and 244 ± 0.12 , CL₂ 131 ± 0.99 , 103 ± 0.92 and 279 ± 0.52 against all four human pathogens The bioactivity results also shows that the ligand L₃ also possess a better antibacterial activity against the tested bacterial strains as compared to Ampicillin. The ligands of L₃ acts as most active antibacterial agent among the all ligands and show better antibacterial activity with MIC 135 ± 0.39 , 122 ± 0.12 , and 130 ± 0.54 , respectively against all four different tested human pathogenic bacterial strains used in this study. All the synthesized ligands were also observed active against *S. Aureus* with MIC ranging from 287 ± 0.16 to 166 ± 0.29 . Whereas, L₁, L₂, L₃, L₄ ligands show better antibacterial activity against *B. Subtilis* with MIC 296 ± 0.34 , 157 ± 0.15 , 130 ± 0.54 , and 166 ± 0.29 respectively. Ligand L₃ Contain Br and showing high antibacterial activity. It was observed that the antibacterial activity was seen in both gram positive and gram negative bacteria.

In the antifungal activity all four ligands shows a better antifungal activity against all two human pathogens compared to *Miconazole*. The ligand L₂ shows better antifungal activity with MIC 76 ± 0.05 and 56 ± 0.72 respectively. The other ligands L₁, L₃ and L₄ also shows a better antifungal 95 ± 0.89 , 79 ± 0.11 , 81 ± 0.38 , 85 ± 0.23 , 101 ± 0.34 , 61 ± 0.90

In the antifungal activity all four Complexes shows a better antifungal activity against all two human pathogens compared to *Miconazole*. The CL₃ complex shows better antifungal activity with MIC 65 ± 0.17 and 61 ± 0.23 against the fungi respectively. The other Complexes CL₂, CL₁ and CL₄ also shows better antifungal activity with MIC 69 ± 0.81 , 44 ± 0.57 , 78 ± 0.62 , 62 ± 0.90 and 89 ± 0.16 , 65 ± 0.76 against all the fungi.

The Ni (II) complex CL₃ contains Br hence it shows more antibacterial and antifungal activity and any other complexes.


The results from the current study are compared to previous reports [38, 39]. From the results of biological activity included in Table 3, it was concluded that almost all the synthesized ligands show good antibacterial activity against at least one of the tested strains whereas most.

Table – 3

Compound	MIC Values in $\mu\text{g/mL}^*$					
	Antibacterial Activity			Antifungal Activity		
	<i>E.coli</i>	<i>P.aeruginosa</i>	<i>S.aureus</i>	<i>B.subtilis</i>	<i>C.Albicans</i>	<i>A.Niger</i>
L ₁	156 \pm 0.38	138 \pm 0.25	287 \pm 0.13	296 \pm 0.34	95 \pm 0.89	79 \pm 0.11
L ₂	194 \pm 0.22	124 \pm 0.47	*	157 \pm 0.15	76 \pm 0.05	56 \pm 0.72
L ₃	135 \pm 0.39	*	122 \pm 0.12	130 \pm 0.54	81 \pm 0.38	85 \pm 0.23
L ₄	187 \pm 0.62	191 \pm 0.54	188 \pm 0.16	166 \pm 0.29	101 \pm 0.34	61 \pm 0.90
CL ₁	115 \pm 0.94	121 \pm 0.74	209 \pm 0.37	244 \pm 0.12	78 \pm 0.62	62 \pm 0.90
CL ₂	131 \pm 0.99	103 \pm 0.92	279 \pm 0.52	*	69 \pm 0.81	44 \pm 0.57
CL ₃	109 \pm 0.21	278 \pm 0.47	106 \pm 0.34	111 \pm 0.66	65 \pm 0.17	61 \pm 0.23
CL ₄	146 \pm 0.09	159 \pm 0.314	155 \pm 0.84	129 \pm 0.72	89 \pm 0.16	65 \pm 0.76
Ampicillin	100 \pm 0.56	100 \pm 0.08	250 \pm 2.29	250 \pm 0.55		
Miconazole	*	*	*	*	25 \pm 0.97	25 \pm 0.58

Thermogravimetric Analysis

Thermogram of the Ni (II) complexes of ligands (L₁, L₂, L₃, and L₄) confirmed four decomposition steps within 100°C and 985°C. The first step in the decomposition takes place after two water molecules are lost, and this occurs within 50°C and 250°C. Steps 1 to 3 in the following sequence: in the range of 200–400°C, 400–600°C, and 600–985°C respectively. Metal oxide remaining as a residue after decomposition takes place. These temperatures correlate to the gradual decomposition of the ligand's organic moiety. Within the temperature range of 40 to 985 °C, the thermogram of the Ni (II) CL₁ complexes exhibited four decomposition phases (Fig.-5). An analytical metal content measurement was used to compare the metal percentages that from metal oxide or metal residues [40].



(Fig.-5) - The thermogram of the Ni (II) CL₁ complexes

Conclusion

In conclusion, the produced Schiff bases were coordinate to the Ni (II) ion through phenolic oxygen atoms and imine nitrogen, acting as a tetradentate ligand. spectrum analysis (FT-IR and UV-visible) TGA measurements are used to confirm that a ligand is attached to a metal ion. In bioactivity the Ni (II) complex CL₁, CL₂, CL₃ and CL₄ shows more better antibacterial and antifungal activity against all human pathogens than the ligand L₁, L₂, L₃ and L₄, because Ni (II) complexes shows bioactivity against all pathogens as compared to ligands. In the above bioactivity the Ni (II) complexes CL₃ is acts as better antimicrobial agent than ligand L₃. Hence Ni (II) Complexes would act as better antimicrobial agent.

References

1. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. *J Antimicrob Chemother* 1997; 39 (Suppl.A):1–6.
2. Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. *Cell* 2007;128(6):1037–50
3. S. P. Jacob, R. Bharathkumar, G. Ashwathram, Aspergillus niger mediated synthesis of ZnO nanoparticles and their antimicrobial and in vitro anti cancerous activity, *World J. Pharm. Res.* 3 (2) (2014) 3044–3054.
4. M.I. Mohamed, M.A. Hapipah, A.A. Mahmood, T.R. Ward, *Polyhedron*, 28 (2009) 3993–3998.

5. Z.C. Liu, B.-D. Wang, Z.-Y. Yang, Y. Li, D.-D. Qin, T.-R. Li, *Eur. J. Med. Chem.* 44 (2009) 4477–4484.
6. Khandar, A.A.; Nejati, K.; Rezvani, Z. Syntheses, Characterization and Study of the Use of Cobalt (II) Schiff–Base Complexes as Catalysts for the Oxidation of Styrene by Molecular Oxygen. *Molecules* 2005, 10, 302–311. [CrossRef] [PubMed]
7. Martell, A.E.; Sawyer, D.T. Oxygen-Co Complexes and Oxygen Activation by Transition Metals; Plenum Press: New York, NY, USA, 1998.
8. Gopalakrishnan M, Sureshkumar P, Kanagarajan V, Thanusu J, Govindaraju R. Silica gel supported sodium hydrogen sulfate as an efficient and reusable heterogeneous catalyst for the synthesis of imines in solvent-free conditions under microwave irradiation. *J Chem Res* 2005; 5:299–303.
9. Gopalakrishnan M, Sureshkumar P, Kanagarajan V, Thanusu J. New environmentally-friendly solvent-free synthesis of imines using calcium oxide under microwave irradiation. *Res Chem Intermed* 2007; 33(6):541–8.
10. Guzen KP, Guarezemini AS, O' rfa~o ATG, Cella R, Pereira CMP, Stefani HA. Eco-friendly synthesis of imines by ultrasound irradiation. *Tetrahedron Lett* 2007;48(10):1845–8.
11. Andrade CKZ, Takada SCS, Alves LM, Rodrigues JP, Suarez PAZ, Branda~o RF, et al. Molecular sieves in ionic liquids as an efficient and recyclable medium for the synthesis of imines. *Synlett* 2004; 12:2135–8.
12. Varma RS, Dahiya R, Kumar S. Clay catalysed synthesis of imines and enamines under solvent-free conditions using microwave irradiation. *Tetrahedron Lett* 1997; 38(12): 2039–42.
13. Schmeyers J, Toda F, Boy J, Kaupp G. Quantitative solid–solid synthesis of azomethines. *J Chem Soc Perkin Trans 2* 1998:989–93.
14. Vass A, Duda's J, Varma RS. Solvent-free synthesis of Nsulfonylimines using microwave irradiation. *Tetrahedron Lett* 1999; 40(27):4951–4.
15. Tanaka K, Shiraishi R. Clean and efficient condensation reactions of aldehydes and amines in a water suspension medium. *Green Chem* 2000;2(6):272–3.
16. Va'zquez MA', Landa M, Reyes L, Miranda R, Tamariz J, Delgado F. Infrared irradiation: effective promoter in the formation of N-benzylideneanilines in the absence of solvent. *Synth Commun* 2004; 34(15):2705–18.
17. K. Buldurun, M. Ozdemir, " J. Mol. Struct. 1202 (2020), 127266.
18. N. Zhang, Y.H. Fan, C.F. Bi, Y. Zhao, X. Zhang, D.M. Zhang, G.M. Huang, *Transition Met. Chem.* 38 (2013) 463.
19. A.P. Arumugam, G. Elango, S. Guhanathan, *European Journal of Biomedical* 6 (2019) 375.
20. S.N. Ahmad, H. Bahron, A.M. Tajuddin, K. Ramasamy, *Malaysian Journal of Fundamental and Applied Sciences* 15 (2019) 613.
21. D.S. Lednicer, *The Organic Chemistry of Drug Synthesis* 27 (1980) 41215.
22. Colin D. *Therapeutic Drugs* 1, Church Livingstone 1, D13-D18, 1999, 111.
23. F. John, L. Rebecca, University of California (CA 94110 USA), *Pharmacotherapy publication* (1998) 831–835
24. F. Baquero, *Journal of Antimicrobial Chemotherapy*, **39**,1 (1997);

https://DOI: 10.1093/jac/39.suppl_1.1

25. M.N. Alekshun, S.B. Levy, *Cell*, **128(6)**, 1037(2007);

<https://DOI: 10.1016/j.cell.2007.03.004>

26. P.A. Ubale, S.P. Kollur, P.A. Bansode, *Inorg. Chim. Act.*, 511, 119846, (2020);
<https://doi.org/10.1016/j.ica.2020.119846>

27. N. Raman, A. Selvan, S. Sudharsan, *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.*, 79 (5) 873 (2011);

<https://doi.org/10.1016/j.saa.2011.03.017>

28. K. Nakamoto, *Infrared Spectra of Inorganic and Coordination compounds*, John Wiley, New York, 1963.

29. I. Vogel, *Quantitative Inorganic Analysis*, Longman, Green and Co., London, 1954.

30. S.E. Turner, R.C. Anderson, *J. Am. Chem. Soc.* 71 (1949) 912.

31. B. Tang, T. Yue, J. Wu, Y. Dong, Y. Ding, H. Wang, *Talanta* 64 (2004) 955.

32. E. Tas, A. Kilic, M. Durgun, I. Yilmaz, I. Ozdemir, N. Gurbuz, *Journal of Organometallic Chemistry* 694 (2009) 446.

33. G. Venkatachalam, R. Ramesh, *Inorg. Chem. Commun.*, 9, 703 (2006);

<https://doi.org/10.1016/j.inoche.2006.04.012>

34. R.G. Kalkhambkar, G.M. Kulkarni, C.M. Kamanavalli, N. Premkumar, S.M. Asdaq, C.M. Sun, *Eur. J. Med. Chem.*, 43, 2178 (2008);

<https://doi.org/10.1016/j.ejmech.2007.08.007>

35. R. Cruickshank, J. P. Duguid, Marmion, B. P., R. H. Swain, *A Medicinal Microbiology*; 2nd ed. Vol. 2, Churchill Livingstone: London, 1975;

36. Collins, A. H. *Microbiological Methods*, 2nd ed.; Butterworth: London, 1976. 32. Khan, Z. K. In vitro and in vivo screening techniques for bioactivity screening and evaluation, *Proc. Int. Workshop UNIDO-CDRI*, 210.33, 1997;

37. (a) B. Duraiswamy, S. K Mishra, V Subhashini, S. A. Dhanraj, B. Suresh, *Indian J. Pharm. Sci.* 68, 389 (2006);

<http://dx.doi.org/10.4103/0250-474X.26671>

(b) A. R. Saundane, K. Rudresh, N. D. Satynarayan, S. P. Hiremath, *Indian J. Pharm. Sci.*, 60, 379 (1989);

(c) K. L. Therese, R. Bhagylaxmi, H. N. Madhavan, P. Deepa, *Indian J. Med. Microbiol.*, 24, 273 (2006);

38. W. Ahmad, K.K. Jaiswal, S. Soni, *Inorg. Nano-Met. Chem.*, 50, 1032 (2020); <https://doi.org/10.1080/24701556.2020.1732419>.

39. P. Goyal, A. Bhardwaj, B.K. Mehta, D. Mehta, *J. Indian Chem. Soc.*, 98 100089 (2021);

<https://doi.org/10.1016/j.jics.2021.100089>.

40. A. A. Nejo, G. A. Kolawole and A. O. Nejo, *Journal of Coordination Chemistry*, 63, 4398 (2010),

<http://dx.doi.org/10.1080/00958972.2010.532871>